Browsing eNauka
Browsing by Project G1 Therapeutics, Inc.
Showing results 1 to 5 of 5
| Issue Date | Title | Author(s) | Type | Мp-cat. |
|---|---|---|---|---|
| 2021 | Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer | Domine, Gomez Manuel; Csoszi, Tibor; Jaal, Jana; Kudaba, Iveta; Nikolov, Krassimir; Radosavljevic, Davorin Z; Xiao, Jie; Horton, Janet K; Malik, Rajesh K; Subramanian, Janakiraman | Article | 21aM21a |
| 2020 | Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer. | Jared, Weiss; Jerome, Goldschmidt; Andric, Zoran G | Conference Paper | Mp. category will be shown later |
| 2021 | Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2). | Goel, Shom; O'Shaughnessy, Joyce; Tan, Antoinette R; Milev-Krastev, Boris; Rugo, Hope S; Aftimos, Philippe Georges; Yardley, Denise A; Andric, Zoran G
Tao, Wenli; Beelen, Andrew Paul; Malik, Rajesh K; Jain, Sarika;
| Conference Paper | Mp. category will be shown later |
| 2019 | Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial | O'Shaughnessy, J; ...; Popovic, Lazar S | Conference Paper | Mp. category will be shown later |
| 2022 | Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study![]() | Tan, Antoinette R; Wright, Gail; Thummala, Anu; Danso, Michael; Popovic, Lazar S | Article | 21a+M21a+ |
